Genomic Health Posts 12 Percent Rise in Q3 Revenues, Secures Ireland Reimbursement | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Genomic Health today said that strong sales of its flagship Oncotype DX breast cancer recurrence test drove a 12 percent increase in third-quarter revenue to $52.1 million from $46.3 million in the comparable period of 2010.

The Redwood City, Calif.-based firm just missed analysts' consensus revenue estimate of $52.3 million for the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The White House has created a list of cuts, including to the NIH, that could be in a budget bill for this year.

The US National Institutes of Health is to allow applicants to cite preprints just as they would any other research paper, ScienceInsider reports.

Two manuscript pages handwritten by Charles Darwin are going on the auction block, according to the Los Angeles Times.

In PNAS this week: tool to track transcriptome-wide binding, evidence of balancing selection on behavior-linked genes, and more.